Economic Impact of Industry Clinical Trials in Europe

Industry clinical trials in are a vital engine of medical innovation and economic growth, with the European Economic Area (EEA) generating €35.7 billion in Gross Value Added (GVA) in 2025 from these activities. This includes €21.7 billion from direct, indirect, and induced effects, €3.6 billion from R&D spillovers, and €10.4 billion from productivity gains via 26.9 million avoided sick days. Supporting 165,000 jobs—45,000 direct in clinical research and over 120,000 indirect—these trials offer patients early access to treatments 5-10 years before launch. EFPIA’s analysis highlights Germany’s lead with €6.3 billion GVA and 37,800 jobs, countering Europe’s shrinking global trial share from 22% in 2013 to 12% in 2023.

Expansion Scenarios Unlock Gains

Three projections assess growth in Europe’s clinical trials: an 11.1% increase per EMA targets, 25% to 2013 levels, or 50% to rival China and North America. These add €4.0 billion, €8.9 billion, or €17.9 billion in EEA GVA, plus 18,000–82,000 jobs and 35,000–158,000 more participants. The modest scenario yields €2.4 billion economic GVA, €0.4 billion spillovers, and €1.2 billion productivity for Germany; the 50% surge hits €5.6 billion.

Frontier Economics used an income-based GVA model from EFPIA R&D data (55% trials share per PhRMA/Eurostat), PwC multipliers, 20% spillover returns, and Chen/Goldman productivity via IQVIA/Boaz data (47% industry trials). Country breakdowns (technical annex) use 2023-2025 data, with conservative US-derived assumptions.

Policy Levers for EU Edge

Strategic actions could elevate EU competitiveness. EFPIA pushes CTIS streamlining, faster starts, and funding to seize EU Biotech Act chances, enhancing spillovers, retention, and leadership for economic-health wins.